418 related articles for article (PubMed ID: 19701690)
1. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA
Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
[TBL] [Abstract][Full Text] [Related]
4. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline.
Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA
Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474
[TBL] [Abstract][Full Text] [Related]
5. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?
Wesseling-Perry K; Tsai EW; Ettenger RB; Jüppner H; Salusky IB
Nephrol Dial Transplant; 2011 Nov; 26(11):3779-84. PubMed ID: 21441401
[TBL] [Abstract][Full Text] [Related]
6. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
[TBL] [Abstract][Full Text] [Related]
7. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
8. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
9. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
10. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1-3.
Sella S; Bonfante L; Fusaro M; Neri F; Plebani M; Zaninotto M; Aghi A; Innico G; Tripepi G; Michielin A; Prandini T; Calò LA; Giannini S
Clin Chem Lab Med; 2020 May; 59(2):343-351. PubMed ID: 32374278
[TBL] [Abstract][Full Text] [Related]
12. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain.
Marcén R; del Castillo D; Capdevila L; Fernandez-Fresnedo G; Rodrigo E; Cantarell C; Fernández-Rodriguez A; López-Oliva MO; Camps J; Aljama P; Ortuño J; Arias M
Transplantation; 2009 May; 87(9):1340-6. PubMed ID: 19424034
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function.
Bleskestad IH; Bergrem H; Leivestad T; Hartmann A; Gøransson LG
Clin Transplant; 2014 Apr; 28(4):479-86. PubMed ID: 25649861
[TBL] [Abstract][Full Text] [Related]
14. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
[TBL] [Abstract][Full Text] [Related]
15. Renal transplant and secondary hyperparathyroidism.
Gøransson LG; Bergrem H
Scand J Urol Nephrol; 2007; 41(6):553-7. PubMed ID: 18050015
[TBL] [Abstract][Full Text] [Related]
16. Microscopic nephrocalcinosis in chronic kidney disease patients.
Evenepoel P; Daenen K; Bammens B; Claes K; Meijers B; Naesens M; Sprangers B; Kuypers D; Lerut E
Nephrol Dial Transplant; 2015 May; 30(5):843-8. PubMed ID: 25586405
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral disorders in pediatric and adolescent renal transplant recipients.
Derakhshan A; Behbahan AG; Lotfi M; Omrani GH; Fallahzadeh MH; Basiratnia M; Al-Hashemi GH
Pediatr Transplant; 2011 Jun; 15(4):367-75. PubMed ID: 21429060
[TBL] [Abstract][Full Text] [Related]
18. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
19. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
20. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
Kanda E; Yoshida M; Sasaki S
BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
